By flow cytometry, we showed that cMO and iMO from DLBCL displayed a higher expression of CD64 and CCR2 (P <.05), without variation in HLA-DR and CD163 (Figure 2D). This evidence concerns the gene CCR2 and diffuse large B-cell lymphoma.